Results 101 to 110 of about 556,132 (392)
Advanced Functional Materials, EarlyView.A bimetallic Mn–Ca nanoreactor (MCC) is developed as a non‐nucleotide STING nanoagonist for cancer metalloimmunotherapy. MCC induces Ca2+ overload and hydroxyl radical generation, resulting in mitochondrial damage and mtDNA release. The released mtDNA cooperates with Mn2+ to robustly activate cGAS–STING signaling.
Xin Wang Mo +7 more
wiley +1 more source
Advanced Functional Materials, EarlyView.The cGAS‐STING pathway boosts HCC antitumor immunity but lacks specific activation. Nanoplatform ZMRPF induces HCC ferroptosis via lipid ROS, releasing mtDNA. It synergizes with ZMRPF‐released Mn2⁺ to activate cGAS‐STING, amplifies antigen‐presenting cell activity, reverses HCC immunosuppression, and enables robust systemic antitumor immunity ...
Yuchen Zhang +13 more
wiley +1 more source
Journal of Transplantation, 2013 Background. No studies have evaluated the impact of multiple generic immunosuppression medications on transplant coordinators (TCs) and patients. Methods.
K. Parker +3 more
doaj +1 more source
Clinical trial of FK 506 immunosuppression in adult cardiac transplantation [PDF]
, 1992 The new immunosuppressive agent FK 506 was used as primary immunotherapy in conjunction with low-dose steroids and azathioprine in 72 patients subsequent to orthotopic cardiac transplantation.
Armitage +17 more
core +1 more source
Synthetic Nanobiology Actuated Lipometabolic Cell Factory for Autologous Tumor Immunotherapy
Advanced Functional Materials, EarlyView.FA plays a crucial role in the interaction between tumor cells and the tumor microenvironment, especially for the immune response. A biocatalytic immunoenhancement strategy is developed to boost antitumor immunity by FA metabolic orientation to ceramide. Through the design of this delicate catalytic immunoenhancement strategy, the synthetic nanobiology
Shoujie Zhao +8 more
wiley +1 more source
Cost of lifetime immunosuppression coverage for kidney transplant recipients. [PDF]
, 2008 On January 1, 2000, Medicare extended the coverage of immunosuppression medications from 3 years to life for elderly and disabled kidney transplant recipients.
Page, Timothy F, Woodward, Robert
core +1 more source
Hepatology, 2019 Tumor‐associated macrophages (TAMs) are recognized as antitumor suppressors, but how TAMs behave in the hypoxic environment of hepatocellular carcinoma (HCC) remains unclear.
Qinchuan Wu +12 more
semanticscholar +1 more source
Advanced Healthcare Materials, EarlyView.Bioengineering tumor‐stroma pancreatic cancer models with potential to emulate the native immunosuppressive tumor microenvironment. Cancer‐on‐a‐bead models exhibited higher relevance for screening immunotherapies and modulating the protumoral PDAC microenvironment. ABSTRACT Pancreatic cancer is notably resistant to treatment, primarily due to its dense
Maria V. Monteiro +4 more
wiley +1 more source
A prospective randomized trial of FK506-based immunosuppression after renal transplantation [PDF]
, 1995 A group of 204 adult patients was entered into a prospective, randomized trial comparing FK506/pred-nisone with FK506/azathioprine/prednisone after renal transplantation between August 1, 1991 and October 11,1992.
Demetris, AJ +12 more
core +1 more source
Advanced Healthcare Materials, EarlyView.We measure the cell‐specific responses of administering infusible ECM (iECM) in acute myocardial infarction (MI) across multiple timepoints. Using single‐nucleus RNA sequencing and spatial transcriptomics, we measure macrophage activation, fibroblast remodeling, increased vascular development, lymphangiogenesis, cardioprotection, and neurogenesis ...
Joshua M. Mesfin +18 more
wiley +1 more source